Ankerstar Wealth’s Vir Biotechnology VIR Stock Holding History

Ankerstar Wealth’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$194	Hold	19	–	–	﹤0.01%	891
2026 Q1	$170	Hold	19	–	–	﹤0.01%	870
2025 Q4	$115	Buy	+19	New	+$113	﹤0.01%	993

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ankerstar Wealth's VIR Position: Q2 2026 in Review

Ankerstar Wealth held its Vir Biotechnology (VIR) position steady in Q2 2026 at 19 shares worth $194. The position accounts for ﹤0.01% of the portfolio, ranked #891.

Ankerstar Wealth first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. 236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Ankerstar Wealth held 19 shares of Vir Biotechnology worth $194 as of Q2 2026.
Ankerstar Wealth left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #891 holding.
Ankerstar Wealth first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.